VRCA vs. XBIT, LPTX, ATOS, ANRO, IVA, NVCT, INZY, TARA, IGMS, and DBVT
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include XBiotech (XBIT), Leap Therapeutics (LPTX), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), Inozyme Pharma (INZY), Protara Therapeutics (TARA), IGM Biosciences (IGMS), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs.
Verrica Pharmaceuticals (NASDAQ:VRCA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.
XBiotech received 150 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 63.98% of users gave Verrica Pharmaceuticals an outperform vote.
XBiotech has lower revenue, but higher earnings than Verrica Pharmaceuticals. XBiotech is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 33.1% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
XBiotech has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. XBiotech's return on equity of -15.99% beat Verrica Pharmaceuticals' return on equity.
Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
In the previous week, XBiotech had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for XBiotech and 0 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.00 equaled XBiotech'saverage media sentiment score.
Verrica Pharmaceuticals currently has a consensus price target of $9.50, indicating a potential upside of 1,302.63%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than XBiotech.
Summary
XBiotech beats Verrica Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 1/20/2025 by MarketBeat.com Staff
